Latest JOHNSON & JOHNSON Stock Portfolio
JOHNSON & JOHNSON Performance:
2025 Q3: 14.11%YTD: 11.32%2024: -5.18%
Performance for 2025 Q3 is 14.11%, and YTD is 11.32%, and 2024 is -5.18%.
About JOHNSON & JOHNSON and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, JOHNSON & JOHNSON reported an equity portfolio of $503.7 Millions as of 30 Sep, 2025.
The top stock holdings of JOHNSON & JOHNSON are PTGX, NBTX, MGTX. The fund has invested 32.3% of it's portfolio in PROTAGONIST THERAPEUTICS INC. and 21.1% of portfolio in NANOBIOTIX S.A.
The fund managers got completely rid off VOR BIOPHARMA, INC. (VOR) and LYELL IMMUNOPHARMA INC. (LYEL) stocks. They significantly reduced their stock positions in RAPPORT THERAPEUTICS, INC.. JOHNSON & JOHNSON opened new stock positions in VOR BIOPHARMA, INC. (VOR) and LYELL IMMUNOPHARMA INC. (LYEL).
The top stock holdings of JOHNSON & JOHNSON are PTGX, NBTX, MGTX. The fund has invested 32.3% of it's portfolio in PROTAGONIST THERAPEUTICS INC. and 21.1% of portfolio in NANOBIOTIX S.A.
The fund managers got completely rid off VOR BIOPHARMA, INC. (VOR) and LYELL IMMUNOPHARMA INC. (LYEL) stocks. They significantly reduced their stock positions in RAPPORT THERAPEUTICS, INC.. JOHNSON & JOHNSON opened new stock positions in VOR BIOPHARMA, INC. (VOR) and LYELL IMMUNOPHARMA INC. (LYEL).
JOHNSON & JOHNSON Annual Return Estimates Vs S&P 500
Our best estimate is that JOHNSON & JOHNSON made a return of 14.11% in the last quarter. In trailing 12 months, it's portfolio return was 13.46%.
New Buys
| Ticker | $ Bought |
|---|---|
| vor biopharma, inc. | 2,617,820 |
| lyell immunopharma inc. | 668,520 |
New stocks bought by JOHNSON & JOHNSON
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| rapport therapeutics, inc. | -28.56 |
JOHNSON & JOHNSON reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| vor biopharma, inc. | -1,139,140 |
| lyell immunopharma inc. | -368,015 |
JOHNSON & JOHNSON got rid off the above stocks
Sector Distribution
JOHNSON & JOHNSON has about 57.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 57.7 |
| Others | 42.3 |
Market Cap. Distribution
JOHNSON & JOHNSON has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 42.3 |
| MID-CAP | 36.5 |
| SMALL-CAP | 13.7 |
| MICRO-CAP | 7.5 |
Stocks belong to which Index?
About 57.7% of the stocks held by JOHNSON & JOHNSON either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 57.7 |
| Others | 42.3 |
JOHNSON & JOHNSON Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of JOHNSON & JOHNSON
JOHNSON & JOHNSON has 20 stocks in it's portfolio. About 97.2% of the portfolio is in top 10 stocks. PRCT proved to be the most loss making stock for the portfolio. PTGX was the most profitable stock for JOHNSON & JOHNSON last quarter.
Last Reported on: 13 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio, inc. | 0.06 | 364,472 | 295,295 | unchanged | 0.00 | ||
| ARWR | arrowhead pharmaceuticals, inc. | 1.70 | 247,598 | 8,539,660 | unchanged | 0.00 | ||
| CVRX | cvrx, inc. | 6.57 | 4,103,430 | 33,114,700 | unchanged | 0.00 | ||
| FATE | fate therapeutics, inc. | 0.84 | 3,379,060 | 4,257,620 | unchanged | 0.00 | ||
| LAB | standard biotools inc | 0.08 | 311,967 | 405,557 | unchanged | 0.00 | ||
| LYEL | lyell immunopharma inc. | 0.13 | 41,165 | 668,520 | new | |||
| LYEL | lyell immunopharma inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MGTX | meiragtx holdings plc | 10.85 | 6,641,060 | 54,656,000 | unchanged | 0.00 | ||
| NBTX | nanobiotix s.a. | 21.09 | 5,623,820 | 106,234,000 | unchanged | 0.00 | ||
| NNOX | nano-x imaging ltd. | 0.12 | 158,852 | 587,752 | unchanged | 0.00 | ||
| PHGE | biomx inc. | 0.01 | 96,866 | 50,855 | unchanged | 0.00 | ||
| PRCT | procept biorobotics corporation | 2.54 | 357,939 | 12,774,800 | unchanged | 0.00 | ||
| PTGX | protagonist therapeutics inc. | 32.30 | 2,449,180 | 162,699,000 | unchanged | 0.00 | ||
| RLYB | rallybio corporation | 0.36 | 3,636,360 | 1,814,540 | unchanged | 0.00 | ||
| SENS | senseonics holdings, inc. | 0.00 | 2,731 | 23,804 | unchanged | 0.00 | ||
| VOR | vor biopharma, inc. | 0.52 | 53,732 | 2,617,820 | new | |||
| VOR | vor biopharma, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| XNCR | xencor, inc. | 1.74 | 748,062 | 8,774,770 | unchanged | 0.00 | ||
| rapport therapeutics, inc. | 10.52 | 1,784,520 | 53,000,200 | reduced | -28.56 | |||
| legend biotech corporation | 5.27 | 814,586 | 26,563,600 | unchanged | 0.00 | |||